Düsseldorf's university hospital, a partner in the CIO cancer centre alliance and a leading site for FAPI and PSMA imaging under Frederik Giesel.
University Hospital Düsseldorf forms, with Aachen, Bonn and Cologne, the Centrum für Integrierte Onkologie (CIO ABCD), a German Cancer Aid Oncology Center of Excellence. Its nuclear medicine department is directed by Frederik Giesel, co-inventor of FAPI PET tracers at Heidelberg, and runs theranostic programmes in prostate and neuroendocrine cancers. The hospital has a large paediatric oncology and haematology department, hepatology and liver cancer programmes, and neurosurgical oncology. Trials from the CIO network give patients access to early-phase immunotherapy and cell therapy studies.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-15.
Matched to Düsseldorf University Hospital, including child institutions. 438 works · 4,188 citations · 69% open access · 7% clinical trials · 2% reviews.
Neurosurgeon who serves as Medical Director and Chair of the Board of University Hospital Düsseldorf, home of the CIO Düsseldorf cancer centre.
Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia.
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Shares FAP-2286 (177Lu / 68Ga), Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
Shares FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares FAPI PET, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, FAPI PET, Lutetium-177 vipivotide tetraxetan.
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/